Melting point: 186-192℃ (dec.)
Specific rotation: -36 º (c=0.74, EtOH)
Boiling point: 900.5±65.0 ℃(Predicted)
Docetaxel is a taxane drug that inhibits the growth of cancer cells by promoting the assembly of microtubule dimers into microtubules, while stabilizing microtubules by preventing the process of demultimerization and blocking cells in G2 and M phases. Mitosis and proliferation. The pharmacological effect of docetaxel is stronger than that of paclitaxel, its intracellular concentration is 3 times higher than that of paclitaxel, and its intracellular retention time is longer, and its affinity for microtubules is 2 times that of paclitaxel; as a microtubule stabilizer and assembly promoter, The activity is 2 times greater than that of paclitaxel; as a microtubule depolymerization inhibitor, the activity is 2 times greater than that of paclitaxel.
It has good curative effect on advanced breast cancer, ovarian cancer and non-small cell lung cancer. It also has certain curative effects on head and neck cancer, pancreatic cancer, small cell lung cancer, gastric cancer, melanoma, and soft tissue sarcoma.
Semi-synthetic from the European yew tree TaxusbaccataL. , 10-deacetylbaccatin III extracted from the needles of Taxaceae is the raw material, and 10-deacetylbaccatin III can be acylated to obtain compound (I). Phenylacrylic acid (330mg, 2.24mmol), dicyclohexylcarbodiimide (DCC, 460mg, 2.24mmol), compound (I) (500mg, 0.56mmol) and 4-dimethylaminopyridine (68mg, 0.56mmol), in Stir at 70°C for 15h under argon. Cool, filter, and wash the filter cake with toluene. The washings and the filtrate were combined and concentrated under reduced pressure. Dichloromethane was added to the residue, washed with 2% aqueous hydrochloric acid, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the remaining 1 g of the residue was purified by column chromatography, eluted with hexane-ethyl acetate (7:3), to obtain 540 mg of compound (II) in a yield of 94%.